Format

Send to

Choose Destination
Cancer Discov. 2018 Jun;8(6):676-678. doi: 10.1158/2159-8290.CD-18-0368.

ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.

Wilson FH1,2,3, Politi K1,3,4.

Author information

1
Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu frederick.wilson@yale.edu.
2
Department of Genetics, Yale School of Medicine, New Haven, Connecticut.
3
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
4
Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Abstract

<b/> A patient with advanced lung adenocarcinoma harboring a CD74-NRG1 gene rearrangement, which promotes ERBB2-ERBB3 heterodimerization and activation of downstream signaling, had an exceptional therapeutic response to an experimental anti-ERBB3 antibody. This result illustrates how NRG1 rearrangements, which are observed at a low frequency in a variety of solid tumors, may represent tractable therapeutic targets. Cancer Discov; 8(6); 676-8. ©2018 AACR.See related article by Drilon et al., p. 686.

PMID:
29858224
PMCID:
PMC6330656
DOI:
10.1158/2159-8290.CD-18-0368
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center